Xact Kapitalforvaltning’s BioMarin Pharmaceuticals BMRN Stock Holding History

Xact Kapitalforvaltning’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$3.02M	Sell	35,716 -3,325	-9%	-$286K	0.06%	251
2019 Q4	$3.3M	Buy	39,041 +1,378	+4%	+$104K	0.06%	309
2019 Q3	$2.54M	Buy	37,663 +5,200	+16%	+$401K	0.05%	348
2019 Q2	$2.78M	Hold	32,463	–	–	0.06%	312
2019 Q1	$2.88M	Sell	32,463 -1,292	-4%	-$120K	0.07%	285
2018 Q4	$2.87M	Buy	33,755 +7,900	+31%	+$752K	0.07%	250
2018 Q3	$2.51M	Buy	25,855 +932	+4%	+$93K	0.05%	338
2018 Q2	$2.35M	Hold	24,923	–	–	0.05%	372
2018 Q1	$2.02M	Buy	24,923 +1,737	+7%	+$149K	0.05%	401
2017 Q4	$2.07M	Buy	23,186 +2,212	+11%	+$192K	0.05%	388
2017 Q3	$1.95M	Buy	20,974 +348	+2%	+$30.8K	0.06%	372
2017 Q2	$1.87M	Sell	20,626 -331	-2%	-$30.1K	0.06%	378
2017 Q1	$1.84M	Buy	20,957 +1,746	+9%	+$155K	0.06%	382
2016 Q4	$1.59M	Sell	19,211 -689	-3%	-$59.3K	0.06%	388
2016 Q3	$1.84M	Buy	+19,900	New	+$1.87M	0.07%	335

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Xact Kapitalforvaltning's BMRN Position: Q1 2020 in Review

Xact Kapitalforvaltning reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.5% in Q1 2020, selling an estimated $286K and leaving 35,716 shares worth $3.02M. The position accounts for 0.06% of the portfolio, ranked #251.

Xact Kapitalforvaltning first reported a position in BMRN in Q3 2016 and has held it in 15 quarters since. The position peaked at $3.3M in Q4 2019. 501 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

Xact Kapitalforvaltning held 35,716 shares of BioMarin Pharmaceuticals worth $3.02M as of Q1 2020.
Xact Kapitalforvaltning sold 3,325 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $286K.
BioMarin Pharmaceuticals made up 0.06% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #251 holding.
Xact Kapitalforvaltning first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 15 quarters since.
Xact Kapitalforvaltning's BioMarin Pharmaceuticals position peaked at $3.3M in Q4 2019.
501 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.